Refreshed content for Sermorelinai_activityai-researcherApr 17, 2026
Pulled 3 linked studies for context.
No external link
Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).
Community effect votes, structured logs, and side-effect summaries.
Effect profile (overview)
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
Last analyzed Apr 17, 20263
Studies indexed
0
Human
0
Animal
0
AI analyzed
Evidence mix0% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: —
Librarian pulse — latest actionsFull changelog ↓
- Apr 17, 12:04 PMRefreshedRefreshed content for Sermorelin
- Apr 16, 5:14 PMRefreshedRefreshed content for Sermorelin
- Apr 16, 5:14 PMRefreshedRefreshed content for Sermorelin
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
Refreshed content for Sermorelinai_activityai-researcherApr 16, 2026
Pulled 3 linked studies for context. - **content** added: Body content generated (1190 chars).
No external link
Refreshed content for Sermorelinai_activityai-researcherApr 16, 2026
Pulled 3 linked studies for context. - **content** added: Body content generated (1183 chars).
No external link
Growth Hormone Deficiency, Empty Sella and Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study.Clinical TrialClinicalTrials.govApr 16, 2026
This study investigated the relationship between growth hormone deficiency, empty sella, and cardio-metabolic risk factors in individuals with obesity. The specific doses of sermorelin administered were not detailed in the abstract. The findings suggest associations but do not establish causation.
Status: COMPLETED
The Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaClinical TrialClinicalTrials.govApr 16, 2026
This study investigated the effects of GHRH (Sermorelin) on sleep promotion and endocrine regulation in service members with traumatic brain injury and insomnia. The specific dose and duration were not reported in the abstract. The outcomes measured included various sleep and endocrine parameters.
Phase: PHASE2Status: WITHDRAWN
Effects of Short-term Growth Hormone in HIV-infected PatientsClinical TrialClinicalTrials.govApr 16, 2026
This study investigated the effects of short-term growth hormone administration in HIV-infected patients. The specific dose and duration of treatment were not reported in the abstract. The outcomes measured were not detailed in the abstract.
Phase: NAStatus: COMPLETED
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat AccumulationClinical TrialClinicalTrials.govApr 16, 2026
This study assessed the efficacy and long-term safety of a 2 mg dose of TH9507, a GHRH analog, in HIV subjects with excess abdominal fat accumulation. The study was multicenter, double-blind, and randomized, comparing TH9507 to placebo. Specific outcomes were not reported in the abstract.
Phase: PHASE3Status: COMPLETED
Inter-Assay Growth Hormone and IGF-I VariabilityClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the variability of growth hormone (GH) and insulin-like growth factor I (IGF-I) measurements across different assays. The analysis included participants receiving Sermorelin, although specific details about the population and dosing were not provided. The findings highlight the importance of assay variability in interpreting GH and IGF-I levels.
Status: WITHDRAWN
Semantic Scholar search for SermorelinStudySemanticScholarDec 12, 2025
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.StudyPubMedDec 12, 2025
International journal of molecular sciences · 2025
Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.StudyPubMedDec 12, 2025
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2025
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Librarian Changelog
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
21h agoRefreshai-researcher85%
Refreshed content for Sermorelin
1d agoRefreshai-researcher85%
Refreshed content for Sermorelin
1d agoRefreshai-researcher85%
Refreshed content for Sermorelin